Publications by authors named "D Bloomfield"

Claim this Profile
S
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial.
Siddharth M Patel, Robert P Giugliano, David A Morrow, Erica L Goodrich, Sabina A Murphy, Dan Bloomfield

JAMA Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis.
Robert Silasi, Ravi S Keshari, Tomohiro Abe, Stephanie D Byrum, Girija Regmi, Dan Bloomfield

J Thromb Haemost· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.
Samer Al Said, Siddharth M Patel, Robert P Giugliano, David A Morrow, Erica L Goodrich, Dan Bloomfield

Circulation· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescription Drug Method-of-Use Patent Protection, 1991-2018.
Doni Bloomfield, Theodore W Teng, Aaron S Kesselheim, S Sean Tu

J Gen Intern Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low concentrations of recombinant activated factor VII normalize coagulation patterns by reversing the changes in viscoelastic testing parameters induced by abelacimab .
Yasser Khder, Serge Côté, Klaus Peter Hoffmann, Debra Freedholm, Dan Bloomfield

Res Pract Thromb Haemost· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis